Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENIALITY
2024-514743-28-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Teprenone with Placebo (2 arms). Primary endpoint: Postoperative atrial fibrillation incidence. Planned start Sep 2024; status: authorised.
02
Drugs
teprenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-514743-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514743-28-00.